1
|
Civardi SC, Besana F, Carnevale Miacca G, Mazzoni F, Arienti V, Politi P, Brondino N, Olivola M. Risk factors for suicidal attempts in a sample of outpatients with treatment-resistant depression: an observational study. Front Psychiatry 2024; 15:1371139. [PMID: 38585482 PMCID: PMC10995380 DOI: 10.3389/fpsyt.2024.1371139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Accepted: 03/08/2024] [Indexed: 04/09/2024] Open
Abstract
Introduction Treatment-resistant depression (TRD) is commonly defined as the failure of at least two trials with antidepressant drugs, given at the right dose and for an appropriate duration. TRD is associated with increased mortality, compared to patients with a simple major depressive episode. This increased rate was mainly attributed to death from external causes, including suicide and accidents. The aim of our study is to identify socio-demographic and psychopathological variables associated with suicidal attempts in a sample of outpatients with TRD. Material and methods We performed a monocentric observational study with a retrospective design including a sample of 63 subjects with TRD referred to an Italian outpatient mental health centre. We collected socio-demographic and psychopathological data from interviews and clinical records. Results 77.8% of the sample (N=49) were females, the mean age was 49.2 (15.9). 33.3% (N=21) of patients had attempted suicide. 54% (N=34) of patients had a psychiatric comorbidity. Among the collected variables, substance use (p=0.031), psychiatric comorbidities (p=0.049) and high scores of HAM-D (p=0.011) were associated with the occurrence of suicide attempts. In the regression model, substance use (OR 6.779), psychiatric comorbidities (OR 3.788) and HAM-D scores (OR 1.057) were predictive of suicide attempts. When controlling for gender, only substance use (OR 6.114) and HAM-D scores (OR 1.057) maintained association with suicide attempts. Conclusion The integrated treatment of comorbidities and substance abuse, which involves different mental health services, is fundamental in achieving the recovery of these patients. Our study supports the importance of performing a careful clinical evaluation of patients with TRD in order to identify factors associated with increased risk of suicide attempts.
Collapse
Affiliation(s)
| | - Filippo Besana
- Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
| | | | - Filippo Mazzoni
- Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
| | - Vincenzo Arienti
- Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
| | - Pierluigi Politi
- Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
- Department of Mental Health and Addictions, Azienda Socio-Sanitaria Territoriale (ASST), Pavia, Pavia, Italy
| | - Natascia Brondino
- Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
- Department of Mental Health and Addictions, Azienda Socio-Sanitaria Territoriale (ASST), Pavia, Pavia, Italy
| | - Miriam Olivola
- Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
- Department of Mental Health and Addictions, Azienda Socio-Sanitaria Territoriale (ASST), Pavia, Pavia, Italy
| |
Collapse
|
2
|
Douka K, Frantzi M, Matthaiakaki-Panagiotaki M, Mazzoni F, Fancelli S, Pilozzi S, Ulivi P, Antonuzzo L, Delmonte A, Roman V, Sigala I, Gianniou N, Kalomenidis I, Makridakis M, Vlahou A, Mischak H, Tsoumakidou M. 205P Modelling of NSCLC aPD1 responses in bronchoscopc biopsies on chip (bronchoBOCs). J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00458-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
3
|
Mazzoni F, Alvisi S, Blokker M, Buchberger SG, Castelletti A, Cominola A, Gross MP, Jacobs HE, Mayer P, Steffelbauer DB, Stewart RA, Stillwell AS, Tzatchkov V, Yamanaka VHA, Franchini M. Investigating the characteristics of residential end uses of water: A worldwide review. Water Res 2023; 230:119500. [PMID: 36640613 DOI: 10.1016/j.watres.2022.119500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 12/14/2022] [Accepted: 12/15/2022] [Indexed: 06/17/2023]
Abstract
A detailed characterization of residential water consumption is essential for ensuring urban water systems' capability to cope with changing water resources availability and water demands induced by growing population, urbanization, and climate change. Several studies have been conducted in the last decades to investigate the characteristics of residential water consumption with data at a sufficiently fine temporal resolution for grasping individual end uses of water. In this paper, we systematically review 114 studies to provide a comprehensive overview of the state-of-the-art research about water consumption at the end-use level. Specifically, we contribute with: (1) an in-depth discussion of the most relevant findings of each study, highlighting which water end-use characteristics were so far prioritized for investigation in different case studies and water demand modelling and management studies from around the world; and (2) a multi-level analysis to qualitatively and quantitatively compare the most common results available in the literature, i.e. daily per capita end-use water consumption, end-use parameter average values and statistical distributions, end-use daily profiles, end-use determinants, and considerations about efficiency and diffusion of water-saving end uses. Our findings can support water utilities, consumers, and researchers (1) in understanding which key aspects of water end uses were primarily investigated in the last decades; and (2) in exploring their main features considering different geographical, cultural, and socio-economic regions of the world.
Collapse
Affiliation(s)
- Filippo Mazzoni
- PhD Student, Department of Engineering, University of Ferrara, Via Saragat 1, Ferrara 44124, Italy.
| | - Stefano Alvisi
- Associate Professor, Department of Engineering, University of Ferrara, Via Saragat 1, Ferrara 44124, Italy
| | - Mirjam Blokker
- Senior Researcher and Lecturer, TU Delft, Faculty of Civil Engineering and Geosciences, Stevinweg 1, Delft, CN 2628, The Netherlands; PhD, KWR Water Research Institute, Groningenhaven 7, Nieuwegein, PE 3433, The Netherlands
| | - Steven G Buchberger
- Professor, Civil and Architecture Engineering and Construction Management Department, University of Cincinnati, 765 Baldwin Hall, 2850 Campus Way Drive, Cincinnati, OH 45221-0071, United States
| | - Andrea Castelletti
- Professor, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Piazza Leonardo da Vinci, 32, Milano 20133, Italy
| | - Andrea Cominola
- Assistant Professor, Chair of Smart Water Networks, Technische Universität Berlin, Straße des 17 Juni 135,, Berlin 10623, Germany; Einstein Center Digital Future, Wilhelmstraße 67, Berlin 10117, Germany
| | - Marie-Philine Gross
- Einstein Center Digital Future, Wilhelmstraße 67, Berlin 10117, Germany; Research Assistant, Chair of Smart Water Networks, Technische Universität Berlin, Straße des 17 Juni 135, Berlin 10623, Germany
| | - Heinz E Jacobs
- Associate Professor, Department of Civil Engineering, Stellenbosch University, Bosman Street, Stellenbosch 7599, South Africa
| | - Peter Mayer
- Water DM Principal and Founder, Water Demand Management LLC, 1339 Hawthorn Avenue, Boulder, CO 80304-2212, United States
| | - David B Steffelbauer
- Group Leader Hydroinformatics, Department of Urban Systems, Kompetenzzentrum Wasser Berlin, Cicerostr. 24, Berlin 10709, Germany
| | - Rodney A Stewart
- Professor, School of Engineering and Built Environment, Griffith University, 1 Parklands Dr, Southport QLD 4215, Australia
| | - Ashlynn S Stillwell
- Associate Professor, Department of Civil and Environmental Engineering, University of Illinois Urbana-Champaign, 205N Mathews Ave, MC-250, Urbana, IL 61801, United States
| | - Velitchko Tzatchkov
- Mexican Institute of Water Technology, Paseo Cuauhnáhuac 8532, Colonia Progreso, Jiutepec, Morelos Mexico
| | - Victor-Hugo Alcocer Yamanaka
- Professor, National Autonomous University of Mexico, Avenida Universidad 3004, Copilco Universidad, Coyoacán, Ciudad de México, Mexico
| | - Marco Franchini
- Professor, Department of Engineering, University of Ferrara, Via Saragat 1, Ferrara 44124, Italy
| |
Collapse
|
4
|
Dedomenici M, Arienti V, Mazzoni F, Politi P, Migliarese G. [Case report: the psychotic-mystical effects related to an unaware use of Salvia divinorum.]. Recenti Prog Med 2022; 113:618-621. [PMID: 36173274 DOI: 10.1701/3888.38708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
It's well known that exotoxicosis can originate various psychiatric clinical pictures. The psychic impact of "classic" substances of abuse is well known and easily detectable with the usual methods of examination. In the last years new psychoactive substances (NPS) are spreading worldwide, determining not easily recognizable situations, with a significant clinical and organizational impact on psychiatry. In this case report, we present a clinical picture treated in hospital and outpatient settings in Vigevano (Pavia - Italy) and characterized by a psychotic onset secondary to an unaware use of Salvia divinorum. After the failure of two psychopharmacological treatment, the patient showed an excellent response to brexiprazole, with substantial restitutio ad integrum in the absence of significant side effects.
Collapse
Affiliation(s)
| | - Vincenzo Arienti
- Dipartimento di Scienze del Sistema Nervoso e del Comportamento, Università di Pavia
| | - Filippo Mazzoni
- Dipartimento di Scienze del Sistema Nervoso e del Comportamento, Università di Pavia
| | - Pierluigi Politi
- Dipartimento di Scienze del Sistema Nervoso e del Comportamento, Università di Pavia
| | | |
Collapse
|
5
|
Camerini A, Mazzoni F, Scotti V, Tibaldi C, Sbrana A, Calabro L, Caliman E, Ciccone L, Grosso M, Chella A, Amoroso D, Baldini E. 1041P Efficacy and safety of chemotherapy after progression on immunotherapy: Results of a multicenter retrospective observational trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
6
|
Pizzutilo E, Agostara A, Oresti S, Signorelli D, Giannetta L, Stabile S, Lauricella C, Amatu A, Brambilla M, Lo Russo G, Proto C, Mazzeo L, Beninato T, Siringo M, Giusti R, Filetti M, Genova C, Barletta G, Russano M, Di Fazio G, Tosoni E, Metro G, Pilotto S, Carta A, Mazzoni F, Roca E, Gelibter A, Gori S, Berardi R, Cerea G, Sartore-Bianchi A, Siena S. EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Andrini E, Lamberti G, Mazzoni F, Riccardi F, Bonetti A, Follador A, Giardina D, Genova C, Guaitoli G, Frassoldati A, Brighenti M, Colantonio I, Pasello G, Ficorella C, Cinieri S, Tiseo M, Gelsomino F, Tognetto M, Rihawi K, Ardizzoni A. EP14.01-006 CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Cappuzzo F, Chiari R, Tiseo M, Minotti V, De Marinis F, Delmonte A, Bungaro M, Cortinovis D, Galetta D, Bonanno L, Chella A, Gridelli C, Morabito A, Grossi F, Bria E, Giannarelli D, Fontanini G, Borra G, Gori S, Mazzoni F, Pilotto S, Landi L. EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, Grossi F, Pizzutilo P, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Marco R, Cantini L, Nigro O, D'Argento E, Buti S, Minuti G, Landi L, Guaitoli G, Lo Russo G, De Toma A, Donisi C, Friedlaender A, De Giglio A, Metro G, Porzio G, Ficorella C, Addeo A. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer. ESMO Open 2021; 6:100078. [PMID: 33735802 PMCID: PMC7988288 DOI: 10.1016/j.esmoop.2021.100078] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 01/26/2021] [Accepted: 02/02/2021] [Indexed: 12/30/2022] Open
Abstract
Background To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated with first-line immunotherapy. Methods Baseline clinical prognostic factors, the neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour cell expression level, lactate dehydrogenase (LDH) and their combination were investigated by a retrospective analysis of 784 patients divided between statistically powered training (n = 201) and validation (n = 583) cohorts. Cut-offs were explored by receiver operating characteristic (ROC) curves and a risk model built with validated independent factors by multivariate analysis. Results NLR < 4 was a significant prognostic factor in both cohorts (P < 0.001). It represented 53% of patients in the validation cohort, with 1-year overall survival (OS) of 76.6% versus 44.8% with NLR > 4, in the validation series. The addition of PD-L1 ≥ 80% (21% of patients) or LDH < 252 U/l (25%) to NLR < 4 did not result in better 1-year OS (of 72.6% and 74.1%, respectively, in the validation cohort). Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 [P < 0.001, hazard ratio (HR) 2.04], pretreatment steroids (P < 0.001, HR 1.67) and NLR < 4 (P < 0.001, HR 2.29) resulted in independent prognostic factors. A risk model with these three factors, namely, the lung immuno-oncology prognostic score (LIPS)-3, accurately stratified three OS risk-validated categories of patients: favourable (0 risk factors, 40%, 1-year OS of 78.2% in the whole series), intermediate (1 or 2 risk factors, 54%, 1-year OS 53.8%) and poor (>2 risk factors, 5%, 1-year OS 10.7%) prognosis. Conclusions We advocate the use of LIPS-3 as an easy-to-assess and inexpensive adjuvant prognostic tool for patients with PD-L1 ≥ 50% aNSCLC. Immunotherapy/chemoimmunotherapy combinations are currently not superior to immunotherapy alone for high PD-L1 aNSCLC. NLR with a cut-off of 4 was validated as an independent prognostic factor for immunotherapy in high PD-L1 aNSCLC. The addition of either PD-L1 ≥ 80% or LDH < 252 U/l to NLR < 4 did not result in better prognostic stratification. The LIPS-3 is a validated 3-class prognostic classification based on the NLR, ECOG PS and pretreatment steroids. The LIPS-3 is a routinely assessable adjuvant prognostic tool for high PD-L1 aNSCLC patients.
Collapse
Affiliation(s)
- G L Banna
- Oncology Department, Portsmouth University Hospitals NHS Trust, Portsmouth, UK
| | - A Cortellini
- Department of Surgery and Cancer, Imperial College London, London, UK; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
| | | | - M Tiseo
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - J G J V Aerts
- Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, the Netherlands
| | - F Barbieri
- Department of Oncology and Hematology, Modena University Hospital, Modena, Italy
| | - R Giusti
- Medical Oncology, St. Andrea Hospital, Rome, Italy
| | - E Bria
- Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy; Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy
| | - F Grossi
- Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - P Pizzutilo
- Thoracic Oncology Unit, Clinical Cancer Center IRCCS Istituto Temorid 'Giovanni Paolo II', Bari, Italy
| | - R Berardi
- Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy
| | - A Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Napoli, Italy
| | - C Genova
- Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - F Mazzoni
- Department of Oncology, Careggi University Hospital, Florence, Italy
| | - V Di Noia
- Medical Oncology, University Hospital of Foggia, Foggia, Italy
| | - D Signorelli
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A Gelibter
- Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy
| | - M Macerelli
- Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine, Italy
| | - F Rastelli
- Medical Oncology, Fermo Area Vasta 4, Fermo, Italy
| | - R Chiari
- Medical Oncology, Ospedali Riuniti Padova Sud 'Madre Teresa Di Calcutta', Monselice, Italy
| | - D Rocco
- Pneumo-Oncology Unit, Monaldi Hospital, Naples, Italy
| | - S Gori
- Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella VR, Italy
| | - M De Tursi
- Department of Medical, Oral & Biotechnological Sciences University G. D'Annunzio, Chieti-Pescara, Chieti, Italy
| | - P Di Marino
- Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy
| | - G Mansueto
- Medical Oncology, F. Spaziani Hospital, Frosinone, Italy
| | - F Zoratto
- Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy
| | - M Filetti
- Medical Oncology, St. Andrea Hospital, Rome, Italy
| | - M Montrone
- Thoracic Oncology Unit, Clinical Cancer Center IRCCS Istituto Temorid 'Giovanni Paolo II', Bari, Italy
| | - F Citarella
- Medical Oncology, Campus Bio-Medico University, Rome, Italy
| | - R Marco
- Medical Oncology, Campus Bio-Medico University, Rome, Italy
| | - L Cantini
- Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, the Netherlands; Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy
| | - O Nigro
- Medical Oncology, ASST-Sette Laghi, Varese, Italy
| | - E D'Argento
- Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy
| | - S Buti
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - G Minuti
- Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy
| | - L Landi
- Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy
| | - G Guaitoli
- Department of Oncology and Hematology, Modena University Hospital, Modena, Italy
| | - G Lo Russo
- Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy
| | - A De Toma
- Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy
| | - C Donisi
- Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
| | - A Friedlaender
- Oncology Department, University Hospital of Geneva, Geneva, Switzerland
| | - A De Giglio
- Division of Medical Oncology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Metro
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy
| | - G Porzio
- Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy
| | - C Ficorella
- Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy
| | - A Addeo
- Oncology Department, University Hospital of Geneva, Geneva, Switzerland
| |
Collapse
|
10
|
Capelletto E, Morabito A, Grossi F, Costanzo FD, Osman G, Chiari R, Bordi P, Scotti V, Romano G, Delmonte A, Galetta D, Ciuffreda L, Manzo A, Genova C, Mazzoni F, Morelli A, Critelli R, Stura I, Migliaretti G, Novello S. Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Danesi R, Petrini I, Mazzoni F, Valleggi S, Gianfilippo G, Pozzessere D, Crucitta S, Restante G, Chella A, Garassino M, Miccoli M, De Re M. Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: A study on circulating tumour DNA. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Mazzoni F, Bongiolatti S, Di Pierro G, Paglialunga L, Scotti V, Ferrari K, Fantechi B, Voltolini L. P3.17-09 Retrospective Analysis of the Efficacy and Safety of Multimodal Treatment for Locally-Advanced NSCLC in Elderly Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Bersanelli M, Castrignanò P, Gambale E, Cortellini A, Tiseo M, Natoli C, Ficorella C, Panni S, Rossetti S, Papa A, Mazzoni F, Facchini G, De Giorgi U, Procopio G, Atzori F, Sava T, De Luca E, Maestri A, Massari F, Buti S. Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx711.039] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Lung Cancer 2017; 115:21-27. [PMID: 29290257 DOI: 10.1016/j.lungcan.2017.11.011] [Citation(s) in RCA: 72] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2017] [Revised: 11/01/2017] [Accepted: 11/13/2017] [Indexed: 12/22/2022]
Abstract
OBJECTIVES EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib. Liquid biopsy, a non-invasive technique used to test the presence of the resistant mutation, may help avoiding tissue re-biopsy. However, analysing only circulating-free DNA, information about other less frequent and coexisting resistance mechanisms may remain unrevealed. MATERIALS AND METHODS All patients reported in this series participated in the ASTRIS trial, a real world treatment study testing the efficacy of osimertinib (80mg os die) in advanced T790M-positive NSCLC progressed to prior EGFR-TKI. Patients were considered eligible to osimertinib if T790M positive on tissue or plasma samples. In our patients, EGFR molecular testing on blood sample was conducted with digital droplet PCR (ddPCR). RESULTS We report our experience of five patients treated with osimertinib after T790M detection on liquid biopsy that presented a disease progression at first tumor assessment mediated by SCLC transformation, as evidenced at tissue re-biopsies. All patients showed low ratio T790M/activating mutation in the blood before osimertinib (lower than 0.03). For three patients, EGFR mutational analysis was T790M-negative when re-assessed by using a less sensitive method (therascreen®) on the same liquid biopsy sample analysed by ddPCR before osimertinib therapy. CONCLUSION Although liquid biopsy is a relevant tool to diagnose T790M presence in NSCLC patients resistant to EGFR-TKI, in case of a low ratio T790M/activating mutation, tissue biopsy should be considered to exclude the presence of SCLC transformation and/or other concomitant resistance mechanisms.
Collapse
Affiliation(s)
- R Minari
- Medical Oncology Unit, University Hospital of Parma, Italy
| | - P Bordi
- Medical Oncology Unit, University Hospital of Parma, Italy
| | - M Del Re
- Clinical Pharmacology and Pharmacogenetic Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy
| | - F Facchinetti
- Medical Oncology Unit, University Hospital of Parma, Italy
| | - F Mazzoni
- Department of Medical Oncology, Careggi Hospital of Firenze, Firenze, Italy
| | - F Barbieri
- Department of Oncology, University Hospital Policlinico of Modena, Modena, Italy
| | - A Camerini
- Medical Oncology, Versilia Hospital, Lido di Camaiore, Italy
| | - C E Comin
- Department of Experimental and Clinical Medicine, Section of Surgery, Histopathology and Molecular Pathology, University of Florence, Italy
| | - L Gnetti
- Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
| | - C Azzoni
- Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
| | - R Nizzoli
- Medical Oncology Unit, University Hospital of Parma, Italy
| | - B Bortesi
- Medical Oncology Unit, University Hospital of Parma, Italy
| | - E Rofi
- Clinical Pharmacology and Pharmacogenetic Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy
| | - P Petreni
- Department of Medical Oncology, Careggi Hospital of Firenze, Firenze, Italy
| | - N Campanini
- Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
| | - G Rossi
- Pathology Unit, Azienda USL Valle d'Aosta, Regional Hospital "Parini", Aosta, Italy
| | - R Danesi
- Clinical Pharmacology and Pharmacogenetic Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy
| | - M Tiseo
- Medical Oncology Unit, University Hospital of Parma, Italy.
| |
Collapse
|
15
|
Mazzoni F, Petreni P, Lunghi A, Vannini A, Brugia M, Mela M, Stefani L, Mascherini G, Galanti G, Di Costanzo F. Physical exercise and eating habits in cancer survivors. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Petreni P, Lunghi A, Mazzoni F, Vannini A, Rispoli A, Brugia M, Stefani L, Petri C, Galanti G, Di Costanzo F. Fast Walking And Resistance Exercise Program In Breast Cancer Survivors. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Mazzoni F, Pasquini M, Pietraperzia G, Becucci M. Determination of binding energy in molecular clusters by ion imaging methods: A test on the phenol–water 1:1 cluster. J Mol Struct 2015. [DOI: 10.1016/j.molstruc.2015.01.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
18
|
Mazzoni F, Pasquini M, Pietraperzia G, Becucci M. Binding energy determination in a π-stacked aromatic cluster: the anisole dimer. Phys Chem Chem Phys 2013; 15:11268-74. [DOI: 10.1039/c3cp50191d] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
19
|
Caramori G, Rigolin GM, Mazzoni F, Leprotti S, Campioni P, Papi A. Circulating endothelial stem cells are not decreased in pulmonary emphysema or COPD. Thorax 2010; 65:554-5. [PMID: 20522859 DOI: 10.1136/thx.2009.121640] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Camerini A, Valsuani C, Mazzoni F, Siclari O, Puccetti C, Donati S, Rondini M, Tartarelli G, Puccinelli P, Di Costanzo F, Amoroso D. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status. Ann Oncol 2009; 21:1290-1295. [PMID: 19914959 DOI: 10.1093/annonc/mdp525] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Elderly patients with advanced non-small-cell lung cancer (NSCLC) with poor performance status (PS) are a special population requiring particular attention. Single-agent oral vinorelbine could be an attractive option. PATIENTS AND METHODS A total of 43 patients with stage IIIB-IV NSCLC and Eastern Cooperative Oncology Group (ECOG) PS of two or more with good functional status were prospectively recruited. Oral vinorelbine was administered at the dose of 60 mg/m(2) on days 1-8 every 3 weeks. Primary end points were response rate and safety. RESULTS Overall response rate was 18.6% with 8 partial responses; 18 of 43 (41.8%) experienced stable disease lasting >12 weeks and 17 of 43 (39.6%) disease progression for an overall clinical benefit of 60.4%. Median time to progression was 4.0 (range 2-22) months and median overall survival 8.0 (range 3-35) months. Treatment was well tolerated. Of 187 cycles, we did not observe any grade 3/4 toxicity with the exception of a single not-febrile G3 neutropenia. Regardless of severity, main toxic effects observed were nausea in 48.1% and vomiting in 22.9% of patients, anemia in 43.2%, fatigue in 32.6% and leukopenia in 23.2%. CONCLUSION Single-agent oral vinorelbine is extremely safe in elderly patients with advanced NSCLC and ECOG PS of two or more and may represent a valid option in this very special population.
Collapse
Affiliation(s)
- A Camerini
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca.
| | - C Valsuani
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca
| | - F Mazzoni
- Department of Medical Oncology, Careggi Hospital and Istituto Toscano Tumori, Firenze, Italy
| | - O Siclari
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca
| | - C Puccetti
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca
| | - S Donati
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca
| | - M Rondini
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca
| | - G Tartarelli
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca
| | - P Puccinelli
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca
| | - F Di Costanzo
- Department of Medical Oncology, Careggi Hospital and Istituto Toscano Tumori, Firenze, Italy
| | - D Amoroso
- Department of Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Lucca
| |
Collapse
|
21
|
Rotella V, Mazzoni F, Pratesi N, Simi L, Orlando C, Boni L, Comin C, Maddau C, Costanzo FD. 9136 Erlotinib as a second-line therapy in advanced non small cell lung cancer: correlation between clinical characteristics and biomarkers. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71849-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
22
|
Di Costanzo F, Gasperoni S, Papaldo P, Bilancia D, Manzione L, Landucci E, Mazzoni F, Cognetti F. Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. Ann Oncol 2006; 17:79-84. [PMID: 16284056 DOI: 10.1093/annonc/mdj033] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Paclitaxel and capecitabine have demonstrated a synergic effect and significant antitumor activity in patients with advanced breast cancer. A weekly schedule of paclitaxel obtained a response rate of 50-68% in advanced breast cancer and less serious side-effects. PATIENTS AND METHODS Thirty-two patients with advanced breast cancer pretreated with chemotherapy were enrolled in a dose-finding trial to determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of paclitaxel given on days 1, 8 and 15 of each cycle combined with capecitabine given twice daily from day 1 through day 14, every 21 days. Three patients were recruited at one of six dose levels (paclitaxel 70-100 mg/m2, capecitabine 1650-2500 mg/m2). RESULTS Thirty-two patients were accrued and 31 were evaluated for toxicity. One DLT has been experienced at level VI as diarrhea grade 3. We determined dose level V as the MTD, but we recommend dose level IV for phase II studies (capecitabine 1250 mg/m2 orally twice daily plus paclitaxel 80 mg/m2 intravenously weekly), owing to cumulative toxicity at level V. The objective response rate was 43%. CONCLUSIONS Weekly paclitaxel plus capecitabine is a safety and active chemotherapy in previously treated metastatic breast cancer.
Collapse
Affiliation(s)
- F Di Costanzo
- U.O. Oncologia Medica, Azienda Ospedaliera Careggi, Firenze, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, Cetto GL, Molino A, Galligioni E, Mansutti M, Tumolo S, Lucentini A, Valduga F, Bartolini S, Crinò L, Conte PF. Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer 2004; 90:31-5. [PMID: 14710202 PMCID: PMC2395340 DOI: 10.1038/sj.bjc.6601518] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
In this phase II, multicentre trial, patients with metastatic breast cancer (MBC) were treated with a combination of gemcitabine, epirubicin and paclitaxel (GET). The primary objective of this study was to determine the tolerability and activity in terms of complete responce (CR) and overall response rate of the GET combination in this patient population. Patients with no prior treatment for MBC, and at least one bidimensionally measurable lesion received gemcitabine 1000 mg m−2 intravenously (i.v.) over 30 min on days 1 and 4, followed by epirubicin i.v. at 90 mg m−2 on day 1, and paclitaxel 175 mg m−2 over 3 h on day 1, every 21 days, up to eight courses. From May 1999 to June 2000, 48 patients were enrolled from seven Italian institutions. A total of 297 chemotherapy courses were administered with a median of six cycles patient−1 (range 1–8). Seven patients (15%) obtained CR and 27 patients (56%) had partial responce, for an overall response rate of 71% (95% CI: 58.3–83.7). After a median follow-up of 23.7 months (range 7.0–34.4), median progression-free survival was 10.5 months (95% CI: 9.2–11.7), and median overall survival 25.9 months. The main haematological toxicity consisted of grade 3 or 4 neutropenia that occurred in 62% of cycles (22% grade 4 and 40% grade 3). The GET combination is active and well tolerated as first-line chemotherapy for MBC.
Collapse
Affiliation(s)
- F Cappuzzo
- Division of Medical Oncology, Bellaria Hospital, via Altura 3, 40139-Bologna, Italy
- Division of Medical Oncology, Bellaria Hospital, via Altura 3, 40139-Bologna, Italy. E-mail:
| | - F Mazzoni
- Division of Medical Oncology, Bellaria Hospital, via Altura 3, 40139-Bologna, Italy
| | - A Gennari
- Division of Medical Oncology, Santa Chiara Hospital and University, Pisa, Italy
| | - S Donati
- Division of Medical Oncology, Santa Chiara Hospital and University, Pisa, Italy
| | - B Salvadori
- Division of Medical Oncology, Santa Chiara Hospital and University, Pisa, Italy
| | - C Orlandini
- Division of Medical Oncology, Santa Chiara Hospital and University, Pisa, Italy
| | - G L Cetto
- Ospedale Civile Maggiore, Verona, Italy
| | - A Molino
- Ospedale Civile Maggiore, Verona, Italy
| | - E Galligioni
- Radiology and Oncology Department, Santa Chiara Hospital, Trento, Italy
| | - M Mansutti
- Division of Medical Oncology, Santa Maria della Misericordia Hospital, Udine, Italy
| | - S Tumolo
- Division of Medical Oncology, Ospedale Civile, Pordenone, Italy
| | - A Lucentini
- Radiology and Oncology Department, Santa Chiara Hospital, Trento, Italy
| | - F Valduga
- Radiology and Oncology Department, Santa Chiara Hospital, Trento, Italy
| | - S Bartolini
- Division of Medical Oncology, Bellaria Hospital, via Altura 3, 40139-Bologna, Italy
| | - L Crinò
- Division of Medical Oncology, Bellaria Hospital, via Altura 3, 40139-Bologna, Italy
| | - P F Conte
- Division of Medical Oncology, Santa Chiara Hospital and University, Pisa, Italy
| |
Collapse
|
24
|
Carducci A, Lucchesi N, Casini B, Mazzoni F, Liaci D, Verani M. Virological analysis of shellfish for food safety and control. Water Sci Technol 2004; 50:137-139. [PMID: 15318499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The present study was performed in order to obtain reliable and applicable techniques of viral detection in shellfish for use in ensuring food safety. This research was developed in two steps: (a) different techniques to recover viruses from artificially contaminated shellfish were tested and (b) the best technique was applied to analyse shellfish collected from sites along the coast of Salento.
Collapse
Affiliation(s)
- A Carducci
- Dept of Experimental Pathology, BMIE, University of Pisa, Pisa, Italy.
| | | | | | | | | | | |
Collapse
|
25
|
Carducci A, Casini B, Bani A, Rovini E, Verani M, Mazzoni F, Giuntini A. Virological control of groundwater quality using biomolecular tests. Water Sci Technol 2003; 47:261-266. [PMID: 12639039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Deep groundwater, even if generally protected, could be contaminated by surface or rain water infiltration through soil fractures, septic tanks, cesspits, land irrigation, disposal of wastewater and disposal of muds from depuration systems. The sanitary importance of such possible contamination is related to the different uses of the water and it is at the maximum level when it is intended for human use. Routine microbiological analyses do not consider viruses, only bacterial parameters, as contamination indicators. However, it is known that enteric viruses can survive a long time in deep aquifers and that they may not always be associated with bacterial indicators. The virological analysis of waters intended for drinking use is provided only as an occasional control exercised at the discretion of the sanitary authority. Technological difficulties with obtaining data about groundwater viral contamination led to a study to devise rapid and efficient methods for their detection and the application of these methods to samples from different sources. Four acid nucleic extraction techniques have been tested (classic proteinase K- phenol/chloroform, QIAamp Viral RNA Kit (Qiagen), SV Total RNA Isolation System (Promega) and NucleoSpin Virus L (Macherey-Nagel). Sensitivity and specificity of RT-PCR protocols for entero- (EV), hepatitis A (HAV) and small round structured (SRSV) viruses have been verified. Deep groundwater samples (100 L) were concentrated (2-step tangential flow ultrafiltration) and the concentrate contaminated with serial 10-fold dilutions of a known titre of poliovirus type 3. Extracted RNA was concentrated (microcon-100) and analysed by RT-PCR using specific EV primers and visualising amplification products by agarose gel electrophoresis. In addition, two different methods of RT-PCR for non-cultivable viruses have been tested: (a) RT-PCR and nested RT-PCR for HAV and (b) RT-PCR with generic primers and RT-PCR with specific primers for SRSV. Different specificity tests have been carried out in the presence of some of the commoner microorganisms. The most efficient, sensitive and specific protocols were used to test 35 x 100L deep groundwater samples. Sample concentrates were split with one part treated with chloroform and analysed by cell culture (BGM and Frp/3, derived from FrHK/4, cells) and the other tested by RT-PCR for HAV, EV and SRSV. Results demonstrated the high efficiency of the classic and QIAamp methods. Microcon-100 did not increase the sensitivity of the technique used. The highest sensitivity was observed for RT-PCR with specific primers for SRSV and for nested RT-PCR for HAV. One sample showed a cytopathic effect, not confirmed at the third subculture, while the RT-PCR allowed the detection of echovirus 7. Cell culture did not allow detection of the majority of the enteric viruses while PCR gave sensitive, specific and rapid detection of a range of agents in the same samples. Even if it was impossible to fix a virological quality standard, it would be necessary to find a viral indicator in order to achieve a complete preventive check which would be particularly useful in some cases (e.g. water never used before, after pollution accidents, for seasonal checking).
Collapse
Affiliation(s)
- A Carducci
- Dept of Experimental Pathology BMIE, University of Pisa, Via S Zeno 35, 56127 Pisa, Italy.
| | | | | | | | | | | | | |
Collapse
|
26
|
Carducci A, Verani M, Casini B, Giuntini A, Mazzoni F, Rovini E, Passaglia A, Giusti L, Valenza A, Lombardi R. Detection and potential indicators of the presence of hepatitis C virus on surfaces in hospital settings. Lett Appl Microbiol 2002; 34:189-93. [PMID: 11874540 DOI: 10.1046/j.1472-765x.2002.01066.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIMS The risk of hepatitis C virus infection in hospital environments can be assessed not only by studying epidemiological data and work practices, but also by the detection of these viruses (or indicators thereof) in health-care settings, on instruments etc. METHODS Since standardized techniques specific to this end do not exist, this study was undertaken to apply methods currently used on clinical samples to the assessment of environmental HCV risk, either through direct detection of the virus (RT-PCR), or by probing for haemoglobin as a potential indicator of blood contamination. The tested techniques were applied in a trial environmental monitoring programme undertaken in various hospital laboratories and clinics, during which total bacterial count determinations were performed in parallel with haemoglobin and hepatitis C virus detection. SIGNIFICANCE AND IMPACT OF THE STUDY The data indicate that the applied methods are of value in detecting low levels of contamination in a hospital environment.
Collapse
Affiliation(s)
- Annalaura Carducci
- Department of Experimental Pathology, Medical Biotechnologies, Infectious Diseases and Epidemiology, University of Pisa, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Carducci A, Cantiani L, Moscatelli R, Casini B, Rovini E, Mazzoni F, Giuntini A, Verani M. Interference between enterovirus and reovirus as a limiting factor in environmental virus detection. Lett Appl Microbiol 2002; 34:110-3. [PMID: 11849505 DOI: 10.1046/j.1472-765x.2002.01056.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIMS Faecal material from raw sewage or other sources lacking effective treatment sometimes contaminates water for human consumption. The relevant Italian regulations therefore call for testing drinking and recreational water for the presence of enterovirus. METHODS AND RESULTS Traditional methods of analysis are based on revealing the typical cytopathic effects of enterovirus on cell cultures. However, the presence in environmental samples of different types of virus may cause interference phenomena that mask such cytopathic effects. The paper reports on an experimental test of this interference hypothesis. Buffalo Green Monkey cell cultures were co-infected via mixed suspensions of the polio type 3 virus and reovirus type 1. Cytopathic effects were then sought and the presence of enterovirus tested for via RT-PCR. CONCLUSIONS, SIGNIFICANCE AND IMPACT OF THE STUDY The results obtained indicate that the normally high sensitivity of tests for the detection of enterovirus in samples is considerably decreased by the simultaneous presence of reovirus.
Collapse
Affiliation(s)
- A Carducci
- Department of Experimental Pathology, Medical Biotechnologies, Infectious Diseases and Epidemiology, University of Pisa, Pisa, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Conte P, Salvadori B, Donati S, Gennari A, Cetto GL, Molino A, Crino L, Mazzoni F, Galligioni E, Mansutti M. The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer. Oncology (Williston Park) 2001; 15:41-3. [PMID: 11252889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Numerous trials have shown that the pharmacokinetic interferences of epirubicin (Ellence)/paclitaxel (Taxol) combinations produce less pharmacodynamic effect than doxorubicin/paclitaxel regimens. Paclitaxel is more easily combined when infused over 3 (as compared to 24) hours; the administration of optimal doses of both agents is important. Based on these findings, a phase II study was performed to evaluate the feasibility and activity of the combination of gemcitabine (Gemzar), epirubicin, and paclitaxel as first-line therapy in advanced breast cancer. Patients received gemcitabine at 1,000 mg/m2 on days 1 and 4, plus epirubicin at 90 mg/m2 on day 1, plus paclitaxel at 175 mg/m2/d on day 1 every 21 days. After six courses, patients less than 60 years old and in complete or partial remission or stable disease were treated with high-dose chemotherapy as consolidation treatment. The overall response rate was 92%, with 31% complete responses; 25 patients received high-dose chemotherapy, achieving a final overall response rate of 97%, with 47% complete responses. At a median follow-up of 25 months, median progression-free survival is 21 months. Grade 4 neutropenia was observed in 64% of patients. Other hematologic toxicities were mild. Mild to moderate peripheral neuropathy was experienced by 39% of patients; grade 2 or 3 mucositis occurred in 25% and 17% of patients, respectively. Based on these results, a multicenter trial has been started in seven Italian centers to confirm the feasibility of this regimen.
Collapse
Affiliation(s)
- P Conte
- Medical Oncology, S. Chiara Hospital, Pisa, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Crinò L, De Marinis F, Scagliotti G, Rinaldi M, Maestri A, Mazzoni F, Di Stefano A, Cappuzzo F, Nelli F, Selvaggi G, Novello S, Gregorc V, Betti M, Tonato M. Gemcitabine—Cisplatin chemotherapy followed by radiotherapy in locally advanced non-small cell lung cancer (nsclc): A phase II retrospective analysis. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80393-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Cappuzzo F, Mazzoni F, Maestri A, Di Stefano A, Calandri C, Crino L. Medical treatment of brain metastases from solid tumours. Forum (Genova) 2000; 10:137-48. [PMID: 10875975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Brain metastases (BrM) are estimated to occur in 20% to 40% of cancer patients, and two-thirds of them become symptomatic during their lifetime. Although every solid tumour may spread to the brain, the risk of developing BrM is higher in lung cancer, breast cancer and melanoma patients. Several findings suggest that the incidence of BrM is rising as a result of advances in imaging procedures and improvements in therapy, which leaves more cancer patients at risk as survival increases. The prognosis of patients with BrM is dependent on the type of the primary tumour. Breast cancer patients have better prognosis than those with BrM from lung, melanoma or colorectal cancer. Patients with BrM from renal cell carcinoma tend to have a poor prognosis. The optimal treatment of patients with BrM continues to evolve. Several factors interfere with the therapeutic strategy, such as histology of primary tumour, patient compliance, localisation, size and number of BrM, and outcome of extracranial disease. Generally, surgery or stereotactic radiotherapy followed by whole brain radiotherapy (WBRT) are indicated in patients with controlled extracranial disease and good performance status presenting an isolated BrM. Adding chemotherapy in this subset of patients is controversial. Supportive care associated with WBRT remains the standard treatment for all patients with multiple symptomatic BrM or with isolated symptomatic BrM in the presence of uncontrolled extracranial disease. For potentially chemosensitive patients with asymptomatic multiple or isolated BrM with disseminated disease, chemotherapy represents the optimal starting therapy.
Collapse
Affiliation(s)
- F Cappuzzo
- Dipartimento di Oncologia Medica, Ospedale Bellaria, Bologna, Italy
| | | | | | | | | | | |
Collapse
|